FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050880665> ?p ?o ?g. }

• W2050880665 endingPage "119" @default.
• W2050880665 startingPage "112" @default.
• W2050880665 abstract "Objective To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. Study design Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders IV. Results Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. Conclusions Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns. To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders IV. Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns." @default.
• W2050880665 created "2016-06-24" @default.
• W2050880665 creator A5000660066 @default.
• W2050880665 creator A5020663339 @default.
• W2050880665 creator A5029493957 @default.
• W2050880665 creator A5032347235 @default.
• W2050880665 creator A5037912308 @default.
• W2050880665 creator A5057922236 @default.
• W2050880665 creator A5070953014 @default.
• W2050880665 creator A5082793937 @default.
• W2050880665 date "2006-07-01" @default.
• W2050880665 modified "2023-10-13" @default.
• W2050880665 title "Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder" @default.
• W2050880665 cites W1519020267 @default.
• W2050880665 cites W1972555665 @default.
• W2050880665 cites W1983302342 @default.
• W2050880665 cites W1990763890 @default.
• W2050880665 cites W1993327116 @default.
• W2050880665 cites W1994020267 @default.
• W2050880665 cites W2008409978 @default.
• W2050880665 cites W2008934160 @default.
• W2050880665 cites W2016483680 @default.
• W2050880665 cites W2024532533 @default.
• W2050880665 cites W2032557741 @default.
• W2050880665 cites W2035623112 @default.
• W2050880665 cites W2044466939 @default.
• W2050880665 cites W2051188089 @default.
• W2050880665 cites W2068742057 @default.
• W2050880665 cites W2081653247 @default.
• W2050880665 cites W2084776993 @default.
• W2050880665 cites W2121519528 @default.
• W2050880665 cites W2122518346 @default.
• W2050880665 cites W2123910896 @default.
• W2050880665 cites W2123980944 @default.
• W2050880665 cites W2129136945 @default.
• W2050880665 cites W2140513029 @default.
• W2050880665 cites W2158377281 @default.
• W2050880665 cites W2167367466 @default.
• W2050880665 cites W2326916472 @default.
• W2050880665 cites W2400633360 @default.
• W2050880665 cites W2518157807 @default.
• W2050880665 cites W2744661960 @default.
• W2050880665 cites W4205984977 @default.
• W2050880665 cites W4245033271 @default.
• W2050880665 cites W4247130871 @default.
• W2050880665 doi "https://doi.org/10.1016/j.jpeds.2006.01.052" @default.
• W2050880665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16860138" @default.
• W2050880665 hasPublicationYear "2006" @default.
• W2050880665 type Work @default.
• W2050880665 sameAs 2050880665 @default.
• W2050880665 citedByCount "91" @default.
• W2050880665 countsByYear W20508806652012 @default.
• W2050880665 countsByYear W20508806652013 @default.
• W2050880665 countsByYear W20508806652014 @default.
• W2050880665 countsByYear W20508806652015 @default.
• W2050880665 countsByYear W20508806652016 @default.
• W2050880665 countsByYear W20508806652017 @default.
• W2050880665 countsByYear W20508806652018 @default.
• W2050880665 countsByYear W20508806652019 @default.
• W2050880665 countsByYear W20508806652020 @default.
• W2050880665 countsByYear W20508806652022 @default.
• W2050880665 countsByYear W20508806652023 @default.
• W2050880665 crossrefType "journal-article" @default.
• W2050880665 hasAuthorship W2050880665A5000660066 @default.
• W2050880665 hasAuthorship W2050880665A5020663339 @default.
• W2050880665 hasAuthorship W2050880665A5029493957 @default.
• W2050880665 hasAuthorship W2050880665A5032347235 @default.
• W2050880665 hasAuthorship W2050880665A5037912308 @default.
• W2050880665 hasAuthorship W2050880665A5057922236 @default.
• W2050880665 hasAuthorship W2050880665A5070953014 @default.
• W2050880665 hasAuthorship W2050880665A5082793937 @default.
• W2050880665 hasConcept C118552586 @default.
• W2050880665 hasConcept C126322002 @default.
• W2050880665 hasConcept C187212893 @default.
• W2050880665 hasConcept C197934379 @default.
• W2050880665 hasConcept C2777112843 @default.
• W2050880665 hasConcept C2778781522 @default.
• W2050880665 hasConcept C2780783007 @default.
• W2050880665 hasConcept C2909253567 @default.
• W2050880665 hasConcept C71924100 @default.
• W2050880665 hasConceptScore W2050880665C118552586 @default.
• W2050880665 hasConceptScore W2050880665C126322002 @default.
• W2050880665 hasConceptScore W2050880665C187212893 @default.
• W2050880665 hasConceptScore W2050880665C197934379 @default.
• W2050880665 hasConceptScore W2050880665C2777112843 @default.
• W2050880665 hasConceptScore W2050880665C2778781522 @default.
• W2050880665 hasConceptScore W2050880665C2780783007 @default.
• W2050880665 hasConceptScore W2050880665C2909253567 @default.
• W2050880665 hasConceptScore W2050880665C71924100 @default.
• W2050880665 hasIssue "1" @default.
• W2050880665 hasLocation W20508806651 @default.
• W2050880665 hasLocation W20508806652 @default.
• W2050880665 hasOpenAccess W2050880665 @default.
• W2050880665 hasPrimaryLocation W20508806651 @default.
• W2050880665 hasRelatedWork W1968417351 @default.
• W2050880665 hasRelatedWork W1969779240 @default.
• W2050880665 hasRelatedWork W2315859520 @default.
• W2050880665 hasRelatedWork W2316132077 @default.

• next